TALPHERA, INC. annual report, FY2022

Filing identity and reporting period

Important metadata discrepancy: The supplied filing is AcelRx Pharmaceuticals, Inc.’s Form 10-K, not a TALPHERA, INC. filing. It reports the fiscal year ended December 31, 2022; it is not a standalone fourth-quarter report.

AcelRx is a specialty pharmaceutical company focused on therapies for medically supervised settings. Its strategic emphasis is shifting to nafamostat candidate Niyad and two pre-filled syringe candidates, while the company planned to divest its sufentanil products DSUVIA and DZUVEO.

Financial performance and liquidity

Metric	FY 2022	FY 2021
Total revenue	$1.771 million	$2.818 million
Product sales	$1.771 million	$1.005 million
Operating loss	$36.633 million	$35.965 million
Net income (loss)	$47.755 million	$(35.099) million
Net cash used in operating activities	$28.331 million	$30.002 million

• 2022 net income was driven principally by an $84.052 million non-cash gain from terminating the royalty monetization liability; it did not indicate profitable operations. Operating loss remained substantial.
• DSUVIA sales revenue was $1.588 million and DZUVEO sales revenue was $0.183 million in 2022. Total product sales rose 76%, but total revenue fell 37% because 2021 included $1.813 million in contract and collaboration revenue, versus none in 2022.
• Cost of goods sold was $2.591 million against $1.771 million of product sales, implying product sales did not cover reported cost of goods sold. Research and development expense increased 27% to $5.193 million; SG&A declined 17% to $25.672 million.
• Cash, cash equivalents, restricted cash and short-term investments totaled $20.770 million at year-end, down from $51.630 million. Of that, $5.0 million was restricted under the loan covenant; unrestricted cash and cash equivalents were $15.275 million, with $0.495 million in short-term investments.
• Oxford debt was approximately $5.4 million outstanding at year-end and scheduled to mature June 1, 2023. The loan requires at least $5.0 million of unrestricted cash and is secured by substantially all assets, subject to stated exceptions.
• The company reported $47.487 million in total assets, $25.673 million in total liabilities and $21.814 million in stockholders’ equity at December 31, 2022. Current assets were $24.566 million and current liabilities $13.770 million.

Material changes versus the prior year

• The January 2022 Lowell acquisition added Niyad and LTX-608. The acquisition was recorded as an asset acquisition, with an $8.819 million in-process research and development asset recognized; up to $26 million of contingent consideration was not recognized at year-end because milestones had not been achieved.
• AcelRx terminated the royalty monetization arrangement in May 2022 for $0.1 million, recognizing the $84.052 million gain and removing the related liability.
• The company recorded a $4.948 million impairment of Zalviso-related equipment and improvements, reflecting no expected near-term U.S. development or European revenue. European authorization for Zalviso was withdrawn in July 2022.
• Headcount fell from 43 at the beginning of 2022 to 19 at year-end; a May 2022 reorganization eliminated approximately 40% of employees, primarily in commercial roles.
• A 1-for-20 reverse stock split became effective October 25, 2022. A December equity financing generated approximately $6.6 million in net proceeds and included substantial warrants; the 2.633 million pre-funded warrants were exercised in the first quarter of 2023.

Outlook, risks and unusual items

• Management stated that existing capital was not expected to fund operations for the next 12 months and that additional capital would be needed. The financial statements and auditor’s report identify substantial doubt about the company’s ability to continue as a going concern. Financing plans—including equity or debt issuance, asset monetization, refinancing, partnerships or divestitures—were not assured.
• As of the filing, AcelRx expected to submit a preliminary EUA application for Niyad in the second quarter of 2023 and pursue a clinical study for full regulatory approval. The EUA pathway is tied to the declared COVID-19 emergency, which the filing said was expected to end May 11, 2023; authorization and commercial prospects were uncertain.
• The company expected to submit the Fedsyra ephedrine pre-filled syringe NDA in the second quarter of 2023 and the phenylephrine syringe NDA in 2024. Fedsyra’s approvability without further development was management’s expectation, not an FDA approval; required supporting data for phenylephrine remained incomplete.
• On March 12, 2023, AcelRx signed an agreement to transfer specified DSUVIA/DZUVEO assets to Alora, with closing expected in April 2023. Subject to closing, AcelRx would receive sales-based payments, including 15% of qualifying net sales and 75% of DoD net sales, plus sales milestones of up to $116.5 million. These amounts depend on the transaction closing and Alora’s commercialization; they are not guaranteed revenue.
• The 10-K reports a material weakness in internal controls over financial reporting and ineffective disclosure controls at year-end. EPS errors required restating the unaudited second- and third-quarter 2022 financial statements. The error did not affect cash, revenue, operating expenses, total net income, balance sheet accounts or cash flows; remediation was underway but not assured.
• Other material risks include dependence on third-party manufacturers and a single nafamostat API supplier, regulatory and clinical uncertainty, limited product revenue, potential dilution, debt repayment, reimbursement and market-acceptance risk, and pending securities-related litigation. The filing states that the litigation loss range could not be estimated.

Key facts investors should verify

• Confirm the intended issuer: the provided document is AcelRx Pharmaceuticals, Inc. (ticker ACRX), not TALPHERA, INC.
• Review the full audited statements and notes for cash runway, restricted cash, debt maturity and subsequent financing or repayment developments; year-end liquidity was limited and management disclosed substantial going-concern doubt.
• Check whether the Alora transaction closed and whether the expected royalties, DoD payments and milestones are being realized.
• Track Niyad’s EUA and IDE/PMA progress, the relevance of the COVID emergency to the EUA pathway, and the timing and regulatory status of both pre-filled syringe applications.
• Assess remediation of the EPS-related material weakness and the effects of warrant issuance, exercise and other potential dilution on the share count.